Projects

Principal Investigator
RNDr. Jana Lomenová, PhD.

National

Current
  • Targeting SERCA Activation: The impact of Novel Derivatives of Cemtirestat on Enhanced Pancreatic Beta-Cell Function in Diabetes Management
    Program: VEGA
    Duration: 1. 1. 2026 – 31. 12. 2029
  • Modulating SERCA Pump Activity: Biochemical Studies in Isolated SERCA1a Enzyme and Pancreatic Beta-Cells.
    Program: VEGA
    Duration: 1. 1. 2026 – 31. 12. 2029
  • Pharmacological Activation of SERCA: A Therapeutic Target for Chronic Metabolic Diseases
    Program: SRDA
    Duration: 1. 9. 2025 – 31. 8. 2029
  • Development of novel selective aldose reductase inhibitors (ARIs) with antioxidant properties and improved bioavailability as potential drugs in prevention of diabetes and cancer
    Program: SRDA
    Duration: 1. 9. 2025 – 31. 8. 2029
  • Targeting SERCA Activation: Therapeutic Strategies for Managing Endoplasmic Reticulum Stress in Chronic Metabolic Diseases
    Program: VEGA
    Duration: 1. 1. 2025 – 31. 12. 2028
  • Targeting SERCA Activation: Therapeutic Strategies for Managing Endoplasmic Reticulum Stress in Diabetic Conditions
    Program: Other projects
    Duration: 1. 1. 2025 – 31. 12. 2026
Finished
  • Can the modulation of sarco-endoplasmic Ca2+ - ATPase (SERCA) by selected natural substances be regulated by sirtuins? Importance in supportive treatment of diabetic complications and tumor diseases
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
  • Multi-target approach to diverse molecular mechanisms of diabetic complications and other glucose toxicity related diseases
    Program: SRDA
    Duration: 1. 8. 2021 – 30. 6. 2025
  • Phenolic compounds and their semi-synthetic derivatives as therapeutic tools for endoplasmic reticulum stress regulation via SERCA pumps
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Development of products by modification of natural compounds and study of their multi-modal effects onCOVID-19 disease
    Program:
    Duration: 1. 7. 2021 – 30. 6. 2023
  • Novel compounds in prevention and treatment of diseases caused by glucose toxicity
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Pharmacological intervention in glucose-toxicity in type 2 diabetes
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
Employees